Home / Company

The company

A small Newark company built around an academic platform.

Company

Saphtx, Inc.

We are a dedicated team of engineers, biologists, and inventors that have a passion for scientific innovation. We engineer protein-based therapeutic strategies for some of the biggest health issues we face. We are at the forefront of translating the innovations and inventions of engineers and scientists in Academia.

The company is based in Newark, New Jersey, and its scientific work is tied to the New Jersey Institute of Technology: the 2019 ocular abstract and the 2024 Nature Communications paper both list NJIT authors, alongside collaborators at Rutgers and the University of Illinois at Chicago.

At a glance

  • Founded2018
  • BasedNewark, New Jersey
  • Website address50 Rector Street, Newark, NJ 07102
  • SBIR address136 4th Ave, Newark, NJ 07104-2608
  • Phone678-613-1386
  • Emailinfo@saphtx.com

Timeline

Five dates

  • 2018

    Founded

    Crustdata records Saphtx Inc. as founded in 2018.

  • 2019

    The ocular hydrogel

    A Biomaterials Society abstract from the New Jersey Institute of Technology presents SAPHTx, an injectable hydrogel of naturally occurring amino acids for neovascular eye disease.

  • 2020

    The STTR solicitation

    NSF solicitation for the Phase I project that became the 2021 award.

  • 2021

    The award, and the website

    NSF STTR Phase I, $255,933, contract 2032392; and saphtx.com goes live with a home page and a COVID-19 page.

  • 2024

    The paper

    “Antiviral fibrils of self-assembled peptides with tunable compositions” is published in Nature Communications.

Aerial view of downtown Newark, New Jersey
Newark, New Jersey. Famartin, CC BY-SA 4.0.

Two addresses

The 2021 website gives 50 Rector Street; the SBIR award record gives 136 4th Ave, Newark, NJ 07104-2608. Both are reproduced as published, and neither is presented as current.

Small, and academic by design

Crustdata records the company as founded in 2018 with a single employee and about $256,000 raised — consistent with the $255,933 Phase I award. This is a translation vehicle for academic work, not a commercial-stage company.

Work with us

Protein-based therapeutics, translated

Saphtx works with academic inventors to translate engineered proteins toward the clinic. If you would like to work with the company, its inbox is public.